RT Journal Article
SR Electronic
T1 Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus
JF BMJ Open Diabetes Research & Care
JO BMJ Open Diab Res Care
FD American Diabetes Association
SP e002745
DO 10.1136/bmjdrc-2021-002745
VO 10
IS 2
A1 Chisa Matsumoto
A1 Hisao Ogawa
A1 Yoshihiko Saito
A1 Sadanori Okada
A1 Hirofumi Soejima
A1 Mio Sakuma
A1 Izuru Masuda
A1 Masafumi Nakayama
A1 Naofumi Doi
A1 Hideaki Jinnouchi
A1 Masako Waki
A1 Takeshi Morimoto
YR 2022
UL http://drc.bmj.com/content/10/2/e002745.abstract
AB Introduction The incidence of atrial fibrillation (AF), a significant risk factor for cardiovascular disease (CVD), is increasing worldwide. Type 2 diabetes mellitus (T2D) and advanced age are recognized as major risk factors for AF, but herein, we evaluated the incidence of AF in elderly patients with T2D and compared the prognosis between these patients with/without AF.Research design and methods The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD2) study is a follow-up cohort study of the JPAD trial, a randomized controlled clinical trial initiated in 2002 in 2535 Japanese patients with T2D, to examine whether low-dose aspirin prevents CVD. After completion of that trial, we followed up the patients until 2019 and evaluated the incidence of AF. We also compared the incidence of cerebral cardiovascular events in elderly patients with T2D with/without AF.Results During the median follow-up period of 10.9 years, 132 patients developed AF (incidence rate: 5.14/1000 person-years). The adjusted HRs for cerebral cardiovascular events, stroke, coronary artery disease, heart failure, and all-cause death in elderly patients with T2D with versus without AF were 1.65 (95% CI 1.03 to 2.66), 1.54 (95% CI 0.81 to 2.93), 1.96 (95% CI 1.03 to 3.73), 5.17 (95% CI 2.46 to 10.89), and 1.82 (95% CI 1.24 to 2.67), respectively.Conclusions Annually, 1 in 200 elderly Japanese patients with T2D are estimated to develop AF. Because elderly patients with T2D with AF are at an elevated risk for CVD, careful follow-up of this patient subgroup is necessary.Trial registration number NCT00110448.Data are available upon reasonable request.